Results 111 to 120 of about 2,530 (165)

Emerging drugs for the treatment of diabetic retinopathy [PDF]

, 2020
Caccioppo, Andrea, Castellino, Niccolò, Porta, Massimo, Reibaldi, Michele, Striglia, Elio   +4 more
core   +1 more source

Advancements in the Treatment of Diabetic Macular Edema: Current Strategies and Future Directions [PDF]

This narrative review examines current and emerging treatment strategies for diabetic macular edema (DME), a complication of diabetic retinopathy characterised by fluid accumulation in the macula, which can lead to vision impairment. The incidence of DME
Bachurska, Dominika, Czach, Magdalena, Czach, Zuzanna, Kopacz, Wojciech, Kruczyk, Barbara, Mazurek, Wojciech, Mazurek, Łukasz, Olędzka, Joanna, Piętak, Mateusz, Rękas, Barbara, Stradczuk , Monika   +10 more
core   +1 more source

Short-Term Outcomes of Intravitreal Brolucizumab Injection and Sub-Tenon Injection of Triamcinolone Acetonide for Diabetic Macular Edema: A Pilot Study. [PDF]

J Vitreoretin Dis
Nagayama M, Terasaki H, Mihara N, Funatsu R, Okamura K, Miyake S, Sonoda S, Sakamoto T.   +7 more
europepmc   +1 more source

Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen. [PDF]

Sci Rep
Kikushima W, Sakurada Y, Fukuda Y, Yoneyama S, Kotoda Y, Tsuru DV, Kashiwagi K.   +6 more
europepmc   +1 more source

U.S. trends of anti-vascular endothelial growth factor use from 2017-2023: An analysis of medicare, medicaid, and commercial insurance. [PDF]

PLoS One
Malhotra K, Colcombe J, Patil S, Vail D, Parikh R.   +4 more
europepmc   +1 more source

International Classification System for Ocular Complications of Anti-VEGF Agents in Clinical Trials [PDF]

\ua9 2024 American Academy of OphthalmologyPurpose: Complications associated with intravitreal anti-VEGF therapies are reported inconsistently in the literature, thus limiting an accurate evaluation and comparison of safety between studies.
Bakri SJ, Balas M, Berrocal A, Chang A, Garg S, Gemmy Cheung CM, Hillier RJ, Holz FG, Huang R, Johnson MW, Kaiser PK, Kertes PJ, Lai TYY, Muni RH, Noble J, Park SS, Paulus YM, Popovic MM, Querques G, Rachitskaya A, Ruamviboonsuk P, Sadda SR, Saidkasimova S, Sandinha MT, Sarraf D, Steel DH, Terasaki H, Weng CY, Williams BK, Wu L   +29 more
core  

Central retinal vein occlusion following intravitreal injections: a case series highlighting multifactorial risk. [PDF]

Int J Retina Vitreous
Antonietti M, Mercado C, Smiddy WE, Schwartz SG.   +3 more
europepmc   +1 more source

Predictive value of uninterrupted dry macula duration for discontinuation of anti-VEGF therapy in diabetic macular edema. [PDF]

Sci Rep
Murata T, Hirano T, Ideta S, Tanaka K, Shimura M.   +4 more
europepmc   +1 more source

Outcomes of Re-Switching Anti-Vascular Endothelial Growth Factor after Brolucizumab-Associated Inflammation in Age-Related Macular Degeneration. [PDF]

Korean J Ophthalmol
Suh YK, Lee SH, Kim MS.
europepmc   +1 more source

Association of Molar Dose and Early Retinochoroidal Blood Flow Changes After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy. [PDF]

Invest Ophthalmol Vis Sci
Kato N, Haruta M, Arai R, Nagae A, Sato K, Furushima K, Yoshida S.   +6 more
europepmc   +1 more source